Vaxman I, et al. - In this retrospective cohort study, researchers assessed the diagnostic and prognostic value of 18-fluoro-2-deoxy-d-glucose positron emission tomography (^[18F] FDG-PET) with computed tomography (CT) (PET/CT) in patients with newly diagnosed marginal zone lymphoma (MZL) treated with immunotherapy, chemotherapy regimens, surgery, or Helicobacter pylori eradication. This study included only patients who had a pretreatment PET/CT (P-PET/CT). Visual assessment and maximal standardized uptake value (SUVmax) were used as methods of evaluation. They used Deauville 5-point score to report interim (I-PET) and end-of-treatment (E-PET) results. Abnormal uptake in any of these methods defined avidity of PET/CT. The avidity of PET at baseline for the whole cohort was 70% (77/110 patients); it was 62.5% (40/64 patients), 76.4% (13/17 patients), and 82.7% (24/29 patients) for MALT lymphoma, for NMZL, and for SMZL, respectively. With a hazard ratio (HR) of 3.4, reduced progression-free survival (PFS) was reported in relation to positive E-PET/CT, when adjusted for IPI, sex, and comorbidities. According to the findings, above 70% of MZL were FDG avid. For PFS, strong prognostic value of positive E-PET/CT was shown.